Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 17/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | PGR | P06401 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | GHSR | Q92847 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30104645 | 1.00 | AR (0.55) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL26365828 | 0.85 | AR (0.49) | AR | |
| SCHEMBL26364955 | 0.85 | AR (0.51) | AR | |
| SCHEMBL30104708 | 0.82 | AR (0.49) | AR | |
| SCHEMBL31125146 | 0.80 | AR (0.65) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL26365041 | 0.79 | AR (0.57) | ARPGR | |
| SCHEMBL28904265 | 0.79 | AR (0.51) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL14289402 | 0.78 | AR (0.59) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL26364963 | 0.78 | AR (0.55) | ARCYP2C19ABCB11ALBPGR | |
| SCHEMBL30104698 | 0.77 | AR (0.59) | ARPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303496-A1 | SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAs) AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
| US-20230303496-A1 | SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAs) AND METHODS OF USE THEREOF | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2023-09-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303496-A1 | SELECTIVE ANDROGEN RECEPTOR COVALENT ANTAGONISTS (SARCAs) AND METHODS OF USE THEREOF | AR, BRCA1, PSMA1 | AR 1/4885CYP2C19 2894/4885ABCB11 4249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.